Elsbach P, Weiss J
Department of Medicine and Microbiology, New York University School of Medicine, New York.
Immunobiology. 1993 Apr;187(3-5):417-29. doi: 10.1016/S0171-2985(11)80354-2.
The bactericidal/permeability-increasing protein (BPI), is a ca. 55 kDa cytotoxic cationic protein of polymorphonuclear leukocytes (PMN) that is present principally in the azurophilic granules. BPI is toxic only toward Gram-negative bacteria. This target specificity is attributable to the strong attraction of BPI for the lipopolysaccharides (LPS) in the bacterial envelope. BPI also binds with high affinity (apparent Kd 2-5 nM) to a broad range of LPS species and potently inhibits the biologic activities of LPS in vitro. A proteolytically prepared or recombinant ca 25 kDa N-terminal fragment of BPI carries all the antibacterial activities of holo-BPI and is more potent than the holo-protein against more resistant bacteria with S-form LPS in their envelope. The fragment is as active as holo-BPI as an LPS-neutralizing agent in vitro and more potently inhibits cytokine induction by S-form Escherichia coli in whole blood ex vivo. Recombinant forms of both proteins protect animals against the lethal effects of administered LPS.
杀菌/通透性增加蛋白(BPI)是一种约55 kDa的细胞毒性阳离子蛋白,存在于多形核白细胞(PMN)中,主要存在于嗜天青颗粒中。BPI仅对革兰氏阴性菌有毒性。这种靶标特异性归因于BPI对细菌包膜中脂多糖(LPS)的强烈吸引力。BPI还以高亲和力(表观Kd为2-5 nM)与多种LPS结合,并在体外有效抑制LPS的生物学活性。经蛋白水解制备或重组的约25 kDa BPI N端片段具有全蛋白BPI的所有抗菌活性,并且在对抗包膜中具有S型LPS的更具抗性的细菌时比全蛋白更有效。该片段在体外作为LPS中和剂与全蛋白BPI活性相当,并且在体外更有效地抑制S型大肠杆菌在全血中诱导细胞因子。两种蛋白的重组形式都能保护动物免受注射LPS的致死作用。